Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Danish Non-inferiority Study of Ocrelizumab and Rituximab in MS (DanNORMS): A Randomized Study Comparing the Efficacy of Ocrelizumab and Rituximab in Active Multiple Sclerosis

NCT04688788 is registered in ClinicalTrials.gov with Rigshospitalet, Denmark as lead sponsor.

NCT NCT04688788
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04688788 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Danish Non-inferiority Study of Ocrelizumab and Rituximab in MS (DanNORMS): A Randomized Study Comparing the Efficacy of Ocrelizumab and Rituximab in Active Multiple Sclerosis
Lead sponsor
Rigshospitalet, Denmark
Phase
Phase 3
Overall status
Active, not recruiting
Start date
April 28, 2021
Completion date
June 10, 2029
Enrollment
600 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

primary progressive multiple sclerosis, relapsing remitting multiple sclerosis, secondary progressive multiple sclerosis